Research Impact

h-index

N/A

Research impact score

Publications

0

Total publications

Trial Results

0

Published trial results

Citations

0

Total citations

Drug Portfolio

Analytics

Trial Phases

Phase 22

Trial Status

Other2

Role Distribution

Principal Investigator2
PI Rate100%

Activity Timeline

Clinical Trials (2)

NCT06020066Phase 2Active Not Recruiting
SRS for NSCLC With Oligo-residual Intracranial Disease After First-line 3rd Generation EGFR-TKI
Brain MetastasesNon-small Cell Lung Cancer
PrincipalinvestigatorStart date: 2023-08-10
NCT06092606Phase 2Unknown
A Multicenter Clinical Trial on DH001 Tablets in the Prevention of Doxorubicin-induced Cardiotoxicity in Cancer Patients
ArrhythmiaCancerDoxorubicin Adverse Reaction+2 more
PrincipalinvestigatorStart date: 2023-04-04

Research Network

Collaboration Network

31 collaborators·73 connections
Network Legend
KOL
Current Investigator
CO
High-influence Collaborator
CO
Collaborator
Click: view details
Double-click: go to profile
Drag: move node

Research Areas & Affiliations

Similar Key Opinion Leaders

Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.

10 similar investigators found

Yufu Li

Henan Cancer Hospital

Similar
1 trials

Shared therapeutic areas:

Arrhythmias, CardiacCancerDoxorubicin Adverse Reaction+2 more

Worked with same sponsors:

Monyan Pharmaceutical (Shanghai) Co., Ltd.
Collaborated on 1 trial
Similarity Score54%

Hui Zhou

Hunan Cancer Hospital

Similar
1 trials

Shared therapeutic areas:

Arrhythmias, CardiacCancerDoxorubicin Adverse Reaction+2 more

Worked with same sponsors:

Monyan Pharmaceutical (Shanghai) Co., Ltd.
Collaborated on 1 trial
Similarity Score54%

Hesheng He

The First Affilaited Hospital of Wannan Medical College

Similar
1 trials

Shared therapeutic areas:

Arrhythmias, CardiacCancerDoxorubicin Adverse Reaction+2 more

Worked with same sponsors:

Monyan Pharmaceutical (Shanghai) Co., Ltd.
Collaborated on 1 trial
Similarity Score54%

Hongmei Jing

Peking University Third Hospital

Similar
4 trials

Shared therapeutic areas:

Arrhythmias, CardiacCancerDoxorubicin Adverse Reaction+2 more

Worked with same sponsors:

Monyan Pharmaceutical (Shanghai) Co., Ltd.
Collaborated on 1 trial
Similarity Score54%

Xiaojia Wang

Zhejiang Cancer Hospital

Similar
2 trials

Shared therapeutic areas:

Arrhythmias, CardiacCancerDoxorubicin Adverse Reaction+2 more

Worked with same sponsors:

Monyan Pharmaceutical (Shanghai) Co., Ltd.
Collaborated on 1 trial
Similarity Score54%

Zhenchang Sun

The First Affiliated Hospital of Zhengzhou University

Similar
1 trials

Shared therapeutic areas:

Arrhythmias, CardiacCancerDoxorubicin Adverse Reaction+2 more

Worked with same sponsors:

Monyan Pharmaceutical (Shanghai) Co., Ltd.
Collaborated on 1 trial
Similarity Score54%

Zhengfei Zhu, MD

Fudan University

Moderately Similar
8 trials

Shared therapeutic areas:

Carcinoma, Non-Small-Cell LungBrain MetastasesCancer

Worked with same sponsors:

Fudan University
Collaborated on 1 trial
Similarity Score34%

Zhenzhou Yang

The Second Affiliated Hospital of Chongqing Medical University

Related
1 trials

Shared therapeutic areas:

Brain MetastasesCarcinoma, Non-Small-Cell Lung

Worked with same sponsors:

Fudan University
Collaborated on 1 trial
Similarity Score24%

Yanyang Wang

General Hospital of Ningxia Medical University

Related
1 trials

Shared therapeutic areas:

Brain MetastasesCarcinoma, Non-Small-Cell Lung

Worked with same sponsors:

Fudan University
Collaborated on 1 trial
Similarity Score24%

Jichen Ren

Jilin Provincial Tumor Hospital

Related
1 trials

Shared therapeutic areas:

Brain MetastasesCarcinoma, Non-Small-Cell Lung

Worked with same sponsors:

Fudan University
Collaborated on 1 trial
Similarity Score24%

Publications (0)

No publications found for this investigator.

Clinical Trials (2)

Showing 2 of 2 trials

NCT06020066Phase 2PrincipalInvestigator

SRS for NSCLC With Oligo-residual Intracranial Disease After First-line 3rd Generation EGFR-TKI

Brain MetastasesNon-small Cell Lung Cancer
Active Not Recruiting
NCT06092606Phase 2PrincipalInvestigator

A Multicenter Clinical Trial on DH001 Tablets in the Prevention of Doxorubicin-induced Cardiotoxicity in Cancer Patients

ArrhythmiaCancerDoxorubicin Adverse Reaction+2 more
Unknown

All 2 trials loaded